|

ZI-MA4-1 (TCR-NK cells) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Zelluna Immunotherapy AS1

Indications

  • Squamous Non-Small Cell Lung Cancer (NSCLC)1
  • Synovial Sarcomas1
  • Head and Neck Cancer1
  • Ovarian Cancer1
  • Lung Cancer1

Other1 trial

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.